Cargando…

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients

AIM: To describe factors associated with treatment failure and frequency of resistance-associated substitutions (RAS). METHODS: Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients starting a first direct-acting antiviral (DAA) regimen before February 2016 and included in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salmon, Dominique, Trimoulet, Pascale, Gilbert, Camille, Solas, Caroline, Lafourcade, Eva, Chas, Julie, Piroth, Lionel, Lacombe, Karine, Katlama, Christine, Peytavin, Gilles, Aumaitre, Hugues, Alric, Laurent, Boué, François, Morlat, Philippe, Poizot-Martin, Isabelle, Billaud, Eric, Rosenthal, Eric, Naqvi, Alissa, Miailhes, Patrick, Bani-Sadr, Firouzé, Esterle, Laure, Carrieri, Patrizia, Dabis, François, Sogni, Philippe, Wittkop, Linda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280155/ https://www.ncbi.nlm.nih.gov/pubmed/30533186 http://dx.doi.org/10.4254/wjh.v10.i11.856

Ejemplares similares

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study
por: Shili-Masmoudi, Sarah, et al.
Publicado: (2019)

Evolution of patients’ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients
por: Yaya, Issifou, et al.
Publicado: (2018)

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort
por: Billa, Oumar, et al.
Publicado: (2018)

HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data)
por: Barré, Tangui, et al.
Publicado: (2022)

Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)
por: Salmon-Ceron, Dominique, et al.
Publicado: (2012)

Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS CO-13 HEPAVIH Cohort)
por: Yaya, Issifou, et al.
Publicado: (2018)

Coffee Intake and Neurocognitive Performance in HIV/HCV Coinfected Patients (ANRS CO13 HEPAVIH)
por: Antwerpes, Saskia, et al.
Publicado: (2020)

HIV-1 Tropism and Liver Fibrosis in HIV–HCV Co-Infected Patients
por: Abravanel, Florence, et al.
Publicado: (2012)

Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort
por: Lacombe, Karine, et al.
Publicado: (2017)

The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010
por: Loko, Marc-Arthur, et al.
Publicado: (2010)

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co‐infected HIV patients with cirrhosis
por: Willemse, Sophie, et al.
Publicado: (2019)

Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)
por: Marcellin, Fabienne, et al.
Publicado: (2022)

Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC)
por: Protière, Christel, et al.
Publicado: (2017)

A H-bond stabilized quinone electrode material for Li–organic batteries: the strength of weak bonds
por: Sieuw, Louis, et al.
Publicado: (2018)

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
por: Martinez, Valrie, et al.
Publicado: (2012)

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
por: Martinez, Valérie, et al.
Publicado: (2013)

Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000
por: Vandenhende, Marie-Anne, et al.
Publicado: (2015)

Severe Morbidity According to Sex in the Era of Combined Antiretroviral Therapy: The ANRS CO3 Aquitaine Cohort
por: Hessamfar, Mojgan, et al.
Publicado: (2014)

Clinical outcomes of DAA and related techniques in hip arthroplasty
por: Driesman, Adam, et al.
Publicado: (2023)

Gaining Greater Insight into HCV Emergence in HIV-Infected Men Who Have Sex with Men: The HEPAIG Study
por: Larsen, Christine, et al.
Publicado: (2011)

Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure
por: Vandenhende, Marie-Anne, et al.
Publicado: (2014)

Treatment of hepatitis C in HIV patients in the new DAA era
por: Soriano, Vicente
Publicado: (2014)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Is DAA Treatment Associated with HBV Reactivation? Results from ERCHIVES
por: Butt, Adeel, et al.
Publicado: (2017)

Treatment of hepatitis C virus genotype 4 in the DAA era
por: Di Biagio, Antonio, et al.
Publicado: (2018)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
por: Danishwar, Mahmood, et al.
Publicado: (2022)

One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort
por: Loubet, Paul, et al.
Publicado: (2023)

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach
por: Cuzin, Lise, et al.
Publicado: (2015)

An Increase of Seawater Temperature Upregulates the Expression of Vibrio parahaemolyticus Virulence Factors Implicated in Adhesion and Biofilm Formation
por: Billaud, Mélanie, et al.
Publicado: (2022)

Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma
por: Poizot-Martin, Isabelle, et al.
Publicado: (2022)

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients
por: Allavena, Clotilde, et al.
Publicado: (2018)

Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
por: Hall, Nolwenn, et al.
Publicado: (2022)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Changing Landscape of Liver Transplantation in the Post-DAA and Contemporary ART Era
por: Saeed, Huma, et al.
Publicado: (2022)

The effect of APN, hs-CRP and APN/hs-CRP in periodontitis with DAA
por: Cheng, Rui, et al.
Publicado: (2023)

Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study
por: de Boissieu, Paul, et al.
Publicado: (2016)

A Dual Polybasic Motif Determines Phosphoinositide Binding and Regulation in the P2X Channel Family
por: Bernier, Louis-Philippe, et al.
Publicado: (2012)

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial
por: Bernardino, Jose I., et al.
Publicado: (2019)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tuvf5mfnt2cfveb056u49pr64j